INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 435m ago
HOUSE PTR35m ago
SEC 13F35m ago
ROBINHOOD CHAIN35m ago
SEC FORM 4/Grant or awardVerified data

Pauza Charles David reported TRAW

Chief Science Officer Virology · Traws Pharma, Inc. · Common Stock

Side
A
Value
—
Shares
18.5K
Price
—
Executed
Dec 12, 2025
Disclosed
Dec 16, 2025
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Dec 12 executedDec 16, 2025 disclosed

TRAW · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
13/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+5 / 25

No reported dollar value · 18.9% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TRAW

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    24
    PN
    Parker Charles NolanChief Financial Officer
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    15.4K sh
    		Dec 12, 2025Apr 8, 2026
    traded Dec 12, 2025
    		+117dSEC FORM 4

    Evidence

    19
    PN
    Parker Charles NolanChief Financial Officer
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    104.5K sh
    		Mar 8, 2026Apr 8, 2026
    traded Mar 8, 2026
    		+31dSEC FORM 4

    Evidence

    24
    PN
    Parker Charles NolanChief Financial Officer
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    61.6K sh
    		Dec 12, 2025Apr 8, 2026
    traded Dec 12, 2025
    		+117dSEC FORM 4

    Evidence

    24
    PN
    Parker Charles NolanChief Financial Officer
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    32.4K sh
    		Oct 12, 2025Apr 8, 2026
    traded Oct 12, 2025
    		+178dSEC FORM 4

    Evidence

    9
    CT
    Clarke TraffordDirector
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    33.4K sh
    		Mar 8, 2026Mar 10, 2026
    traded Mar 8, 2026
    		+2dSEC FORM 4

    Evidence

    9
    RR
    Redfield RobertChief Medical Officer
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    108.9K sh
    		Mar 8, 2026Mar 10, 2026
    traded Mar 8, 2026
    		+2dSEC FORM 4

    Evidence

    9
    PD
    Pauza Charles DavidChief Science Officer Virology
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    118.4K sh
    		Mar 8, 2026Mar 10, 2026
    traded Mar 8, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SN
    Savchuk NikolayDirector, Chief Operating Officer
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    96.9K sh
    		Mar 8, 2026Mar 10, 2026
    traded Mar 8, 2026
    		+2dSEC FORM 4

    Evidence

    13
    SN
    Savchuk NikolayDirector, Chief Operating Officer
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    16.4K sh
    		Dec 12, 2025Dec 16, 2025
    traded Dec 12, 2025
    		+4dSEC FORM 4

    Evidence

    9
    PD
    Pauza Charles DavidChief Science Officer Virology
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    73.9K sh
    		Dec 12, 2025Dec 16, 2025
    traded Dec 12, 2025
    		+4dSEC FORM 4

    Evidence

    9
    RR
    Redfield RobertChief Medical Officer
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    65.7K sh
    		Dec 12, 2025Dec 16, 2025
    traded Dec 12, 2025
    		+4dSEC FORM 4

    Evidence

    13
    RR
    Redfield RobertChief Medical Officer
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    16.4K sh
    		Dec 12, 2025Dec 16, 2025
    traded Dec 12, 2025
    		+4dSEC FORM 4

    Evidence

    9
    SN
    Savchuk NikolayDirector, Chief Operating Officer
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    65.7K sh
    		Dec 12, 2025Dec 16, 2025
    traded Dec 12, 2025
    		+4dSEC FORM 4

    Evidence

    9
    CT
    Clarke TraffordDirector
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    24.6K sh
    		Dec 12, 2025Dec 16, 2025
    traded Dec 12, 2025
    		+4dSEC FORM 4

    Evidence

    9
    CT
    Clarke TraffordDirector
    TRAWTraws Pharma, Inc.
    Grant or award
    		A—
    6,157 sh
    		Dec 12, 2025Dec 16, 2025
    traded Dec 12, 2025
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002018150-25-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 12, 2025
    Published
    Dec 16, 2025
    Ingested by INSIDER
    Nov 5, 04:27 UTC
    Last re-read
    Nov 5, 04:27 UTC

    Extracted facts

    Filer
    Pauza Charles David
    Role
    Chief Science Officer Virology
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Traws Pharma, Inc.
    Ticker
    TRAW
    Shares
    18.5K
    Price per share
    $0
    Execution date (reported)
    Dec 12, 2025
    Owned after transaction
    116.0K shares
    Days from execution to publication
    4

    What this establishes

    Pauza Charles David filed this Form 4 reporting a grant or award of TRAW on Dec 12, 2025. It became public on Dec 16, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Science Officer Virology
    Pauza Charles Davidcik:0002018150
    Issuer
    Traws Pharma, Inc.cik:0001130598

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.